Therapeutic approaches in myelofibrosis

Giovanni Barosi, Vittorio Rosti, Alessandro M. Vannucchi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Introduction: Myeloproliferative neoplasm (MPN)-associated myelofibrosis is the most disabling of the classical Philadelphia-negative MPNs. The discovery that a gain-of-function mutation of JAK2 (JAK2V617F) is present in more than 60% of patients with MPN-associated myelofibrosis has provided a new target for innovative treatment strategies. Areas covered: This review discusses the indications and limitations of conventional therapies employed for the treatment of MPN-associated myelofibrosis before reviewing the information available for new therapies, including the immunomodulatory and demethylating agents, histone deacethylase, mammalian target of rapamycin (mTOR) and JAK2- inhibitors. The Medline and ASH databases were searched for clinical trials on the medical therapy of MPN-associated myelofibrosis from early 2000 to December 2010. Expert opinion: Three categories of drugs have proved to have significant activity in MPN-associated myelofibrosis. Up to a 40% response rate on anemia has been reported with the immunomodulator, pomalidomide. The m-TOR inhibitor RAD-001 and various JAK2 inhibitors have documented a profound effect on splenomegaly and constitutional symptoms, with some also having activity on anemia. These new drugs will give physicians more options to tailor therapeutic choice in this challenging disease.

Original languageEnglish
Pages (from-to)1597-1611
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number10
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Primary Myelofibrosis
Second Primary Neoplasms
Anemia
Therapeutics
Neoplasms
Immunomodulation
Splenomegaly
Expert Testimony
Immunologic Factors
Sirolimus
Pharmaceutical Preparations
Histones
Clinical Trials
Databases
Physicians
Mutation

Keywords

  • demethylating agents
  • histone deacetylase inhibitors
  • JAK2 inhibitors
  • JAK2 V617F mutation
  • mTOR inhibitors
  • myelofibrosis
  • myeloproliferative neoplasm
  • response criteria

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Therapeutic approaches in myelofibrosis. / Barosi, Giovanni; Rosti, Vittorio; Vannucchi, Alessandro M.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 10, 07.2011, p. 1597-1611.

Research output: Contribution to journalArticle

Barosi, Giovanni ; Rosti, Vittorio ; Vannucchi, Alessandro M. / Therapeutic approaches in myelofibrosis. In: Expert Opinion on Pharmacotherapy. 2011 ; Vol. 12, No. 10. pp. 1597-1611.
@article{85fa5e735844468c9d4a716f4fb58123,
title = "Therapeutic approaches in myelofibrosis",
abstract = "Introduction: Myeloproliferative neoplasm (MPN)-associated myelofibrosis is the most disabling of the classical Philadelphia-negative MPNs. The discovery that a gain-of-function mutation of JAK2 (JAK2V617F) is present in more than 60{\%} of patients with MPN-associated myelofibrosis has provided a new target for innovative treatment strategies. Areas covered: This review discusses the indications and limitations of conventional therapies employed for the treatment of MPN-associated myelofibrosis before reviewing the information available for new therapies, including the immunomodulatory and demethylating agents, histone deacethylase, mammalian target of rapamycin (mTOR) and JAK2- inhibitors. The Medline and ASH databases were searched for clinical trials on the medical therapy of MPN-associated myelofibrosis from early 2000 to December 2010. Expert opinion: Three categories of drugs have proved to have significant activity in MPN-associated myelofibrosis. Up to a 40{\%} response rate on anemia has been reported with the immunomodulator, pomalidomide. The m-TOR inhibitor RAD-001 and various JAK2 inhibitors have documented a profound effect on splenomegaly and constitutional symptoms, with some also having activity on anemia. These new drugs will give physicians more options to tailor therapeutic choice in this challenging disease.",
keywords = "demethylating agents, histone deacetylase inhibitors, JAK2 inhibitors, JAK2 V617F mutation, mTOR inhibitors, myelofibrosis, myeloproliferative neoplasm, response criteria",
author = "Giovanni Barosi and Vittorio Rosti and Vannucchi, {Alessandro M.}",
year = "2011",
month = "7",
doi = "10.1517/14656566.2011.568939",
language = "English",
volume = "12",
pages = "1597--1611",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - Therapeutic approaches in myelofibrosis

AU - Barosi, Giovanni

AU - Rosti, Vittorio

AU - Vannucchi, Alessandro M.

PY - 2011/7

Y1 - 2011/7

N2 - Introduction: Myeloproliferative neoplasm (MPN)-associated myelofibrosis is the most disabling of the classical Philadelphia-negative MPNs. The discovery that a gain-of-function mutation of JAK2 (JAK2V617F) is present in more than 60% of patients with MPN-associated myelofibrosis has provided a new target for innovative treatment strategies. Areas covered: This review discusses the indications and limitations of conventional therapies employed for the treatment of MPN-associated myelofibrosis before reviewing the information available for new therapies, including the immunomodulatory and demethylating agents, histone deacethylase, mammalian target of rapamycin (mTOR) and JAK2- inhibitors. The Medline and ASH databases were searched for clinical trials on the medical therapy of MPN-associated myelofibrosis from early 2000 to December 2010. Expert opinion: Three categories of drugs have proved to have significant activity in MPN-associated myelofibrosis. Up to a 40% response rate on anemia has been reported with the immunomodulator, pomalidomide. The m-TOR inhibitor RAD-001 and various JAK2 inhibitors have documented a profound effect on splenomegaly and constitutional symptoms, with some also having activity on anemia. These new drugs will give physicians more options to tailor therapeutic choice in this challenging disease.

AB - Introduction: Myeloproliferative neoplasm (MPN)-associated myelofibrosis is the most disabling of the classical Philadelphia-negative MPNs. The discovery that a gain-of-function mutation of JAK2 (JAK2V617F) is present in more than 60% of patients with MPN-associated myelofibrosis has provided a new target for innovative treatment strategies. Areas covered: This review discusses the indications and limitations of conventional therapies employed for the treatment of MPN-associated myelofibrosis before reviewing the information available for new therapies, including the immunomodulatory and demethylating agents, histone deacethylase, mammalian target of rapamycin (mTOR) and JAK2- inhibitors. The Medline and ASH databases were searched for clinical trials on the medical therapy of MPN-associated myelofibrosis from early 2000 to December 2010. Expert opinion: Three categories of drugs have proved to have significant activity in MPN-associated myelofibrosis. Up to a 40% response rate on anemia has been reported with the immunomodulator, pomalidomide. The m-TOR inhibitor RAD-001 and various JAK2 inhibitors have documented a profound effect on splenomegaly and constitutional symptoms, with some also having activity on anemia. These new drugs will give physicians more options to tailor therapeutic choice in this challenging disease.

KW - demethylating agents

KW - histone deacetylase inhibitors

KW - JAK2 inhibitors

KW - JAK2 V617F mutation

KW - mTOR inhibitors

KW - myelofibrosis

KW - myeloproliferative neoplasm

KW - response criteria

UR - http://www.scopus.com/inward/record.url?scp=79958697713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958697713&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.568939

DO - 10.1517/14656566.2011.568939

M3 - Article

C2 - 21457082

AN - SCOPUS:79958697713

VL - 12

SP - 1597

EP - 1611

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -